Precis Medicamentos reported that the immunizing agent is 81% effective and that the antibodies produced in the application are able to neutralize variants of the virus
The pharmaceutical company Need Medicines presented to National Health Surveillance Agency (Anvisa) a request for authorization from emergency use gives Covaxin, vaccine produced by the Indian laboratory Bharat Biotech against a Covid-19. The information was released by the Brazilian company on Monday, 8. In a note sent to the press, Precis informed that the immunizing agent has an 81% effectiveness and that the antibodies produced in the application are able to neutralize variants of the virus. Also according to the pharmaceutical company, the documentation sent to the agency is part of the pre-submission stage, “according to Anvisa’s Emergency Use Guide”. If the immunizer is approved, Bharat Biotech stated that it will send “4 million doses vaccine, out of a total of 20 million previously contracted ”to the Ministry of Health, all of which will be used in the public health system.
Applied in two doses, Covaxin has been administered since January this year in the India, with millions of doses being used to immunize the local population. According to the pharmaceutical company, the immunizer “demonstrated the most important outcome of efficacy, protection against serious illness since the vaccination impulse”, which validated the safety evidence from the first tests carried out. The company’s expectation is that the release of the immunizer will contribute to the National Plan for Operationalization of Vaccination against Covid-19, from the Ministry of Health. To date, more than 40 countries have shown interest in purchasing doses of the immunizer.